SCHEMBL182671

SCHEMBL182671

Nc1ncc(Br)cc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
KMT2A Q03164 2/20 0.54
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
IDO1 P14902 1/20 0.43
MTOR P42345 1/20 0.39
DYRK1A Q13627 2/20 0.39
MAP3K12 Q12852 4/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TNF P01375 1/20 0.36
KDM1A O60341 2/20 0.36
PIK3CA P42336 2/20 0.35
CHEK1 O14757 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21031807 0.78 GLA (0.45) MTORMAP3K12POLBTNFPIK3CA
SCHEMBL29601287 0.78 GLA (0.45) MTORMAP3K12POLBTNFPIK3CA
SCHEMBL1577509 0.78 HTT (0.41) HTTKMT2APLA2G1BATG4BIDO1
SCHEMBL29427052 0.78 HTT (0.41) HTTKMT2APLA2G1BATG4BIDO1
SCHEMBL26023718 0.77 CYP11B1 (0.42) HTTKMT2APLA2G1BATG4BIDO1
SCHEMBL18072106 0.77 MTOR (0.40) IDO1MTORMAP3K12TNFPIK3CA
SCHEMBL3643010 0.77 ALDH1A1 (0.43) KMT2AMTORMAP3K12MEN1POLB
SCHEMBL29858053 0.76 KMT2A (0.50) HTTKMT2APLA2G1BATG4BIDO1
SCHEMBL1254830 0.76 KMT2A (0.50) HTTKMT2APLA2G1BATG4BIDO1
SCHEMBL24661519 0.75 CYP11B1 (0.38) HTTKMT2APLA2G1BATG4BIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731207-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2026-04-29 EP disclosed
US-12473303-B2 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use Carrick Therapeutics Limited (IE) 2025-11-18 US disclosed
US-20250340552-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS HOTSPOT THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 US disclosed
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES SIGNAL PHARMACEUTICALS, LLC 2025-09-04 US disclosed
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2025-06-24 US disclosed
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 WO disclosed
US-20070167460-A1 Acetylenyl-pyrazolo-pyrimidine derivatives MCARTHUR SILVIA G 2007-07-19 US disclosed
US-7238808-B2 Acetylenyl-pyrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2007-07-03 US disclosed
WO-2007039439-A1 OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070072879-A1 Novel compounds as metabotropic glutamate receptor antagonists HOFFMANN-LA ROCHE INC. 2007-03-29 US disclosed
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-09-28 US disclosed
WO-2006099972-A1 ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-09-28 WO disclosed
EP-0031218-B1 A 2-AMINO-TRIFLUOROMETHYL-HALOGENOPYRIDINE COMPOUND AND A PROCESS FOR PRODUCING THE SAME ISHIHARA SANGYO KAISHA LTD. (JP) 1983-05-11 EP disclosed
US-4349681-A 2-Amino-3-chloro-5-trifluoromethylpyridine ISHIHARA SANGYO KAISHA, LTD. (JP) 1982-09-14 US disclosed
EP-0031218-A1 A 2-amino-trifluoromethyl-halogenopyridine compound and a process for producing the same ISHIHARA SANGYO KAISHA LTD. (JP) 1981-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340552-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, PNLIP, GOT2 HTT 428/4885KMT2A 2857/4885PLA2G1B 848/4885
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, HAX1, HRH4 HTT 91/4885KMT2A 3502/4885PLA2G1B 3731/4885
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, TPMT, ACAT1 HTT 1390/4885KMT2A 1079/4885PLA2G1B 1008/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 HTT 4666/4885KMT2A 1382/4885PLA2G1B 685/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HTT 1112/4885KMT2A 440/4885PLA2G1B 2760/4885
US-20070167460-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, ADORA2B, TPMT HTT 1306/4885KMT2A 1196/4885PLA2G1B 1127/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B HTT 2728/4885KMT2A 684/4885PLA2G1B 2082/4885
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF APOL1, APOB, LDLR HTT 1460/4885KMT2A 4679/4885PLA2G1B 759/4885
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 HTT 91/4885KMT2A 3502/4885PLA2G1B 3731/4885
US-12473303-B2 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use CDK3, CDK1, CDK2 HTT 1128/4885KMT2A 531/4885PLA2G1B 2341/4885
US-20070072879-A1 Novel compounds as metabotropic glutamate receptor antagonists GRM1, GRM2, GRM3 HTT 1387/4885KMT2A 769/4885PLA2G1B 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.